A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.
RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback